Pharmacokinetics of recombinant human granulocyte macrophage colony-stimulating factor in Macaca mulatta.
OBJECTIVE
To examine the pharmacokinetics of i.v. and s.c. recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) in Macaca mulatta.


METHODS
Plasma levels of rhGM-CSF were detected with sandwich enzyme-linked immunosorbent assay.


RESULTS
Plasma concentration-time curves after i.v. rhGM-CSF in monkeys were best fitted with 3-compartment model. The 1st, 2nd, and 3rd phase T1/2 were 0.05-0.07, 0.14-0.58, and 1.4-4.1 h. Cl and K10 were similar between different doses, respectively. Cmax was 0.93 +/- 0.16 microgram.L-1, Tmax was 2.65 +/- 0.14 h, and elimination T1/2 was 2.5 +/- 0.3 h after s.c. rhGM-CSF. The bioavailability after s.c. rhGM-CSF was 0.61.


CONCLUSIONS
Pharmacokinetics of rhGM-CSF in Macaca mulatta provided a useful index for clinical trial.
Wang
R G
RG
Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China.
Zhu
X Z
XZ
Song
W
W
D000818:Animals; D001682:Biological Availability; D004797:Enzyme-Linked Immunosorbent Assay; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000493:pharmacokinetics*; D008253:Macaca mulatta; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor